StemCells Inc. (STEM) This Palo Alto company is involved in the discovery and development of adult stem cell therapeutics for treating damage to the central nervous system, liver, and pancreas. Negative earnings, P/S is a high 1771.

LifeCell Corporation (LIFC) This New Jersey company develops and sells human-derived tissue-based products for use in reconstructive, orthopedic, and urogynecologic surgery. They produce a three-dimensional structured regenerative human tissue matrix. P/E 45, P/S 6.3.

MedImmune (MEDI) This Maryland company develops, manufactures, and markets products for the treatment of infectious diseases, inflammatory diseases, and cancer. P/E 167, P/S 6.2.

AVI Biopharma (AVII) The Oregon based company is involved in the development of therapeutic products based on NEUGENE antisense technology to treat various diseases. Negative earnings, P/S is 100.

Celera Group (CRA) This NYSE company, founded in 1937, is involved in the discovery and validation of new diagnostic markers, using proprietary genomics and proteomics discovery platforms and diagnostic products based on those markers. They collaborate with Abbott Laboratories, Genentech, General Electric and Merck. Negative earnings, P/S is 24.

Cellgene (CELG) This New Jersey company is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. Their primary product includes THALOMID, for the treatment of erythema nodosum leprosum. Last year, the company received patent on placental stem cell recovery. P/E is 316, P/S is 21.

Curis, Inc. (CRIS) This Massachusetts based company is involved in the discovery, development, and marketing of products that modulate key regulatory signaling pathways which control the repair and regeneration of human tissues and organs. It collaborates with Genentech, Procter & Gamble, and Wyeth. Negative earnings, P/S is 4.9.

Dendreon Corporation (DNDN) This company is involved in the discovery, development, and marketing of active immunotherapies, monoclonal antibodies, and small molecule product candidates to treat cancer. They manufacture the DACSÒSC stem cell enrichment device. Negative earnings, very high P/S of 1500.